Status: Recruiting
SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment
This is a prospective, single-arm, single-center, Phase II clinical study designed to assess the preliminary efficacy and safety of SKB264 Plus Inetetamab plus inetetamab for the treatment of HER2-positive, unresectable, locally advanced or metastatic breast cancer following progression on prior T-DXd therapy.
Participants needed: 48
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Fudan UniversityUpdated: Jul 15, 2026Locations: 1
Eligibility criteria
Age ≥ 18 years, male or female. [+13]
Meningeal metastases confirmed by MRI or lumbar puncture. [+18]